[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624703":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":28,"locations":34,"responsibleParty":169,"collaborators":11,"id":171,"slug":11,"hasResults":172,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":172,"sex":178,"minAge":179,"maxAge":11,"enrollmentInfo":180,"targetDuration":11,"studyType":183,"phases":184,"briefSummary":186,"conditions":187,"keywords":11,"overallStatus":190,"whyStopped":11,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":200},{"fullName":5,"class":6},"Region Skane","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"80 bpm","ACTIVE_COMPARATOR",null,[13],"Device: Increasing the pacemaker lower rate",{"label":15,"type":6,"description":11,"interventionNames":16},"60 bpm",[17],"Device: Standard setting",[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DEVICE","Increasing the pacemaker lower rate","Increasing the pacemaker lower rate from 60 to 80 bpm",[9],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"Standard setting","Lower rate setting of 60 bpm",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},"Arash Mokhtari, MD, PhD","CONTACT","+4646171000","arash.mokhtari.0561@med.lu.se",[35,53,68,84,97,110,125,140,154],{"facility":36,"status":11,"city":37,"state":11,"zip":11,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Aarhus University Hospital","Aarhus","Denmark",{"type":40,"coordinates":41},"Point",[42,43],10.21076,56.15674,{"lat":43,"lon":42},[46,50],{"name":47,"role":31,"phone":48,"phoneExt":11,"email":49},"Steen Hvitfeldt Poulsen, MD, PhD","+45 7846 1698","steen.hvitfeldt@rm.dk",{"name":51,"role":52,"phone":11,"phoneExt":11,"email":11},"Steen Hvitfeldt Poulsen","PRINCIPAL_INVESTIGATOR",{"facility":54,"status":11,"city":55,"state":11,"zip":11,"country":38,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Rigshospitalet","Copenhagen",{"type":40,"coordinates":57},[58,59],12.56553,55.67594,{"lat":59,"lon":58},[62,66],{"name":63,"role":31,"phone":64,"phoneExt":11,"email":65},"Mads Ersbøll, MD, PhD","+4535 45 35 45","mads.kristian.ersboell.02@regionh.dk",{"name":67,"role":52,"phone":11,"phoneExt":11,"email":11},"Mads Ersbøll",{"facility":69,"status":11,"city":70,"state":11,"zip":11,"country":71,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Sahlgrenska University Hospital","Gothenburg","Sweden",{"type":40,"coordinates":73},[74,75],11.96679,57.70716,{"lat":75,"lon":74},[78,82],{"name":79,"role":31,"phone":80,"phoneExt":11,"email":81},"Entela Bollano, MD, PhD","+46313421000","entela.bollano@vgregion.se",{"name":83,"role":52,"phone":11,"phoneExt":11,"email":11},"Entela Bollano",{"facility":85,"status":11,"city":86,"state":11,"zip":11,"country":71,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Linköping University Hospital","Linköping",{"type":40,"coordinates":88},[89,90],15.62157,58.41086,{"lat":90,"lon":89},[93],{"name":94,"role":31,"phone":95,"phoneExt":11,"email":96},"Henriette Henriette van der Wal, MD, PhD","+4610-103 00 00","Henriette.van.der.Wal@regionostergotland.se",{"facility":98,"status":11,"city":99,"state":11,"zip":11,"country":71,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Skane University Hospital","Lund",{"type":40,"coordinates":101},[102,103],13.19321,55.70584,{"lat":103,"lon":102},[106,107,108],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},{"name":11,"role":31,"phone":11,"phoneExt":11,"email":33},{"name":109,"role":52,"phone":11,"phoneExt":11,"email":11},"Arash Mokhtari",{"facility":111,"status":11,"city":112,"state":11,"zip":11,"country":71,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Skellefteå Hospital","Skellefteå",{"type":40,"coordinates":114},[115,116],20.95279,64.75067,{"lat":116,"lon":115},[119,123],{"name":120,"role":31,"phone":121,"phoneExt":11,"email":122},"Kurt Boman, MD, PhD","+4690-785 00 00","kurt.boman@regionvasterbotten.se",{"name":124,"role":52,"phone":11,"phoneExt":11,"email":11},"Kurt Boman",{"facility":126,"status":11,"city":127,"state":11,"zip":11,"country":71,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"Karolinska University Hospital","Stockholm",{"type":40,"coordinates":129},[130,131],18.06871,59.32938,{"lat":131,"lon":130},[134,138],{"name":135,"role":31,"phone":136,"phoneExt":11,"email":137},"Per Eldhagen, MD, PhD","+468-123 700 00","per.eldhagen@regionstockholm.se",{"name":139,"role":52,"phone":11,"phoneExt":11,"email":11},"Per Eldhagen",{"facility":141,"status":11,"city":142,"state":11,"zip":11,"country":71,"cosmosGeoPoint":143,"geoPoint":147,"contacts":148},"Norrland University Hospital","Umeå",{"type":40,"coordinates":144},[145,146],20.25972,63.82842,{"lat":146,"lon":145},[149,152],{"name":150,"role":31,"phone":121,"phoneExt":11,"email":151},"Björn Pilebro, MD, PhD","Bjorn.Pilebro@regionvasterbotten.se",{"name":153,"role":52,"phone":11,"phoneExt":11,"email":11},"Björn Pilebro",{"facility":155,"status":11,"city":156,"state":11,"zip":11,"country":71,"cosmosGeoPoint":157,"geoPoint":161,"contacts":162},"Academic University Hospital","Uppsala",{"type":40,"coordinates":158},[159,160],17.63889,59.85882,{"lat":160,"lon":159},[163,167],{"name":164,"role":31,"phone":165,"phoneExt":11,"email":166},"Tymon Pol, MD, PhD","+4618-611 00 00","tymon.pol@medsci.uu.se",{"name":168,"role":52,"phone":11,"phoneExt":11,"email":11},"Tymon Pol",{"type":170,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100624703",false,"NCT07413081","Increased Pacemaker Lower Rate in ATTR Cardiac Amyloidosis","Increased Pacemaker Lower Rate in ATTR Cardiac Amyloidosis: a Randomized, Crossover Clinical Trial (PACE-ATTR)","PACE-ATTR","Inclusion Criteria:\n\n* ATTR-CM defined as one of the following:\n* a.Positive cardiac biopsy for ATTR amyloidosis\n* b.Positive extra-cardiac biopsy for ATTR amyloidosis AND cardiac involvement demonstrated by CMR or echocardiography\n* c.Grade 2-3 uptake on DPD-scintigraphy AND negative serum free light chain and negative urine and serum immunofixation AND cardiac involvement demonstrated by CMR or echocardiography\n* Ongoing treatment with a transthyretin stabilizer or silencer OR considered not to be a candidate for these therapies with no planned initiation during the study period.\n* NYHA functional class II-III\n* Pre-existing pacemaker and either:\n* a.Atrial pacing with minimal RV pacing (\\\u003C2%), or\n* b.His bundle or left bundle branch area pacing, or\n* c.Biventricular pacing, or\n* d.Ongoing RV pacing with a high degree of RV pace (\\>80%)\n* NT-proBNP \\>600 ng\u002FL\n* Age ≥18 years\n* Ability and willingness to provide written informed consent\n* Pacing \\>80% with a programmed lower rate of 60 (AAI\u002FCSP\u002FCRT\u002FRV-pace)\n\nExclusion Criteria:\n\n* Inability to perform the 6-minute walk test.\n* Planned coronary revascularization, ablation of atrial flutter\u002Ffibrillation, or any severe (obstructive or regurgitant) valvular heart disease expected to require intervention during the trial in the investigator's opinion.\n* MI, unstable angina, coronary revascularization (percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)), ablation of atrial flutter\u002Ffibrillation, cardioversion, valve repair\u002Freplacement, hospitalization for decompensated heart failure or cardiac resynchronisation therapy within 12 weeks prior to enrollment.\n* Planned upgrade to CRT or conduction system pacing in patients with RV pacing.\n* More than moderate valvular stenosis or regurgitation\n* Inability of the patient, in the opinion of the investigator, to understand and\u002For comply with procedures and\u002For follow-up OR any conditions that, in the opinion of the investigator, may render the patient unable to complete the study\n* Presence of any other disease than heart failure with a life expectancy of \\\u003C 1year in the investigators opinion\n* Enrollment in other interventional device or drug trials during the study period, with the exception of open label extension studies\n* Listed for cardiac transplantation\n* Initiation of SGLT2-inhibitor or mineralocorticoid receptor antagonist within 4 weeks prior to enrollment\n* Initiation or change in loop diuretic therapy within 4 weeks prior to enrollment","ALL","18 Years",{"count":181,"type":182},34,"ESTIMATED","INTERVENTIONAL",[185],"NA","In cardiac amyloidosis, the heart muscle becomes thick and stiff, making it difficult to pump enough blood with each beat. The heart also often cannot increase its stroke volume, making patients with cardiac amyloidosis more dependent on having an adequate heart rate. Many develop conduction problems and need a pacemaker. In a related condition, heart failure with preserved ejection fraction, setting a higher pacemaker rate improved patients' quality of life. It is not known if the same benefits apply to amyloidosis. This study will test whether raising the pacemaker rate improves well-being and daily function in affected patients.",[188,189],"Cardiac Amyloidosis","Pacemaker","NOT_YET_RECRUITING","2026-02-09",{"date":193,"type":194},"2026-02-17","ACTUAL",{"date":196,"type":182},"2026-02-01",{"date":198,"type":182},"2027-12-31",{"name":5,"class":6},9]